05:40 PM EST, 02/05/2025 (MT Newswires) -- Myriad Genetics ( MYGN ) said Wednesday the US Patent and Trademark Office issued two new patents to the company, further advancing the process of its molecular residual disease assay.

US patent No. 12,215,391 relates to proprietary automated methods to carry out molecular residual disease analysis, the company said late Wednesday. Patent No. 12,215,392 relates to the "patient journey" aspects of the disease.

The assay will be able to tell clinicians and patients if the treatment is and if the cancer has recurred, Myriad Chief Executive Paul Diaz said.